NPCE

NeuroPace is executing a clean growth story: revenue has more than doubled from $45.2M (FY2021) to $100.0M (FY2025), up 25.1% year-over-year, on a gross margin of 77.2% that reflects the differentiated, hard-to-replicate RNS System — per MD&A, 'the first and only commercially available, brain-responsive neuromodulation system.' Just as important, the losses are compressing every year: net income has narrowed from -$47.1M (FY2022) to -$21.5M (FY2025) and operating cash burn improved ~39% to -$11.0M. With capex near zero ($332K), the path toward self-funding is visible, and at a P/S of 5.4 for a 25% grower with software-like gross margins, the valuation is fair rather than stretched. This is a quality franchise being priced reasonably.

What keeps this a hold rather than a buy is the balance sheet and the binary regulatory setup. Stockholders' equity is just $19.0M against $86.5M of liabilities (4.55x) and a $552M accumulated deficit; liquidity is $61.1M of cash and short-term investments (MD&A) against a $58.9M term loan — the company is essentially levered one-for-one against its cash while still burning it. The eye-catching $49.5M of cash paid for stock repurchase in FY2025, alongside a 3.4% rise in shares outstanding, is unusual capital allocation for a business that isn't yet cash-generative and deserves scrutiny before adding aggressively.